Authors
Abdu Mohammad, Samhitha Gundakaram, Adamsegd Isac Gebremedhen, Benjamin J Becerra, Mohammad Ebad Ur Rehman, Mamdouh Souleymane, Stephen Roy, Samson T Teka, Donald Lynch
Published in
Transplantation and cellular therapy. Nov 10, 2026. Epub Nov 10, 2026.
Abstract
Patients receiving chimeric antigen receptor (CAR) T-cell therapy are at increased risk for infection and sepsis due to malignancy-related immune dysfunction, lymphodepleting chemotherapy, and immunosuppression used to treat CAR T-cell toxicities; however, nationally representative estimates of sepsis burden and economic impact remain limited.
This study uses nationally representative U.S. data to evaluate patient characteristics, clinical outcomes, and healthcare utilization associated with sepsis among hospitalizations involving CAR T-cell therapy.
Adult hospitalizations for acute lymphoblastic leukemia, non-Hodgkin lymphoma, or multiple myeloma in which CAR T-cell therapy was administered between 2017 and 2022 were identified from the National Inpatient Sample (NIS) and stratified by sepsis status. After excluding records with missing covariates, survey-weighted analyses were performed to generate nationally representative estimates. Multivariable regression models were used to evaluate differences in mortality and secondary outcomes, with statistical significance defined as a two-sided p value < 0.05.
Among 10,450 weighted CAR T-cell therapy hospitalizations, 645 (6.2%) were complicated by sepsis. In-hospital mortality was significantly higher in hospitalizations with sepsis (28.7% vs 1.1%; adjusted odds ratio [aOR] 33.96; 95% confidence interval [CI] 18.67-61.75). Sepsis was independently associated with higher odds of acute kidney injury (aOR 4.31), respiratory failure (aOR 11.85), acute hepatic failure (aOR 44.42), and septic shock (aOR 411.05), along with greater use of renal replacement therapy, mechanical ventilation, and vasopressors. Thrombohemorrhagic events were more frequent among hospitalizations with sepsis, including disseminated intravascular coagulation (aOR 9.30), acute venous thromboembolism (aOR 2.95), acute coronary syndrome (aOR 27.63), acute ischemic stroke (aOR 7.53), gastrointestinal hemorrhage (aOR 6.47), and intracranial hemorrhage (aOR 4.84), as well as increased need for cryoprecipitate and fresh frozen plasma transfusion (aOR 2.70). Sepsis was also associated with longer hospital stay (adjusted incidence rate ratio [aIRR] 1.96) and higher hospitalization charges (adjusted charge ratio [aCR] 1.22).
Sepsis was documented in approximately 6% of CAR T-cell hospitalizations and was associated with higher in-hospital mortality, organ dysfunction, critical-care utilization, longer hospitalization, and higher hospitalization charges. These findings highlight the substantial clinical and healthcare burden associated with sepsis in this population.
PMID:
43009022
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0